{
    "Trade/Device Name(s)": [
        "iLet\u00ae Dosing Decision Software"
    ],
    "Submitter Information": "Beta Bionics, Inc.",
    "510(k) Number": "K220916",
    "Predicate Device Reference 510(k) Number(s)": [
        "K200467"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QJI"
    ],
    "Summary Letter Date": "December 20, 2022",
    "Summary Letter Received Date": "December 20, 2022",
    "Submission Date": "May 17, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1356"
    ],
    "Regulation Name(s)": [
        "Interoperable Automated Glycemic Controller"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Capillary blood"
    ],
    "Specimen Container(s)": [
        "Blood glucose meter",
        "Continuous glucose monitor sensor"
    ],
    "Instrument(s)/Platform(s)": [
        "iLet ACE Pump",
        "Integrated continuous glucose monitor (iCGM)",
        "Self-monitoring blood glucose (SMBG) meter"
    ],
    "Method(s)/Technology(ies)": [
        "Automated glycemic control algorithm",
        "Interoperable medical device software"
    ],
    "Methodologies": [
        "Adaptive insulin titration",
        "Autonomous dose determination"
    ],
    "Submission Type(s)": [
        "Software",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Beta Bionics iLet Dosing Decision Software for autonomous insulin dosing in type 1 diabetes management using CGM and ACE pump integration",
    "Indications for Use Summary": "Intended for management of type 1 diabetes mellitus in individuals 6 years or older, autonomously determining and commanding insulin dosing based on CGM and meal announcements, compatible with ACE pumps and SMBG meter for temporary manual input.",
    "fda_folder": "Clinical Chemistry"
}